Key insights
- CONMED's upcoming earnings report is under scrutiny due to competitive pressures on its AirSeal system from Intuitive Surgical. Analysts have a hold rating, reflecting concerns about market share and lack of catalysts. Investors will focus on AirSeal's performance and portfolio optimization progress. The stock has already declined significantly, and further weakness is possible if earnings disappoint.
CONMED Corporation is set to report first-quarter results after the market close Wednesday, with investors focused on whether the medical device maker can stem competitive pressures that have sent shares tumbling 40% from their 52-week high.
Analysts expect the company to post earnings per share of 82 cents on revenue of $310.6 million, representing year-over-year declines of 13.8% and 3.3%, respectively. The projected results would also mark a sharp sequential drop from the fourth quarter’s $1.43 EPS and $373.2 million in revenue, though first-quarter weakness is typical for the industry.
All five analysts covering CONMED rate the stock a hold, with a mean price target of $44.75—implying 21.6% upside from the current $36.79 share price. EPS estimates have remained flat over the past 60 days, suggesting analysts see little near-term catalyst for improvement.
That pessimism reflects mounting concerns over the company’s flagship AirSeal insufflation system. Piper Sandler downgraded CONMED from Buy to Hold in March, slashing its price target to $39 from $55, citing competitive threats and execution missteps. Analyst Matt O’Brien noted that "AirSeal did not completely implode following the introduction of a competitive product from ISRG," referring to Intuitive Surgical, but said the company lacks identifiable catalysts to reverse two years of stock underperformance.
What Investors Are Watching
The central question is whether AirSeal can maintain its position as Intuitive Surgical’s robotic platforms gain share in laparoscopic and robotic surgery. AirSeal supports procedures with lower-pressure insufflation that reduces pain and shortens recovery, but investors will scrutinize any commentary on competitive dynamics and market share trends.
Management’s progress on portfolio optimization will also be in focus. CONMED announced plans to exit its gastroenterology product lines to fully align operations within its core markets—minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Investors will want evidence that this strategic narrowing can drive improved execution.
Leadership stability is another concern following CFO Todd Garner’s departure effective March 15, with the executive remaining in an advisory role through November. Any updates on the CFO search or strategic direction under the interim finance leadership could influence sentiment.
Looking Ahead
CONMED exceeded expectations in the fourth quarter, posting adjusted EPS of $1.43 versus the $1.32 consensus, demonstrating the company can still execute operationally. Management has guided to full-year 2026 revenue of $1.345 billion to $1.375 billion and adjusted EPS of $4.30 to $4.45.
Whether today’s results and guidance commentary can convince skeptical analysts that the worst is behind CONMED—or whether competitive and execution headwinds will persist—will determine if the stock can begin clawing back its losses from a 52-week high of $61.08.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.